New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
10:44 EDTRPRXRepros expects to report results for Phase 2 vaginal Proellex study in 1Q13
Sees fully enrolling 1 year Dexa study in Q1. Expects to request Androxal pre-NDA meeting with FDA for 1Q14 in 4Q13. Comments from slides that will be presented at the 2013 Biotech Showcase Conference.
News For RPRX From The Last 14 Days
Check below for free stories on RPRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
13:57 EDTRPRXRepros Therapeutics volatility increases on wide price movement
Repros Therapeutics overall option implied volatility of 128 is above its 26-week average of 89 according to Track Data, suggesting large price movement.
09:18 EDTRPRXRepros Therapeutics provides update on Androxal
Subscribe for More Information
September 18, 2014
13:38 EDTRPRXRepros needed unique Androxal label even before ADCOM panel, says Ladenburg
Ladenburg said that given the FDA advisory committee's 20 to 1 vote that it believes the FDA will likely revise testosterone replacement therapy labels to restrict their use in hypogonadal patients with clear etiology. However, Ladenburg added that Repros was always going to have to establish a unique label for Androxal and the firm believes that the company's ongoing and completed trials will provide sufficient data for filing and approval by the FDA in secondary hypogonadism. The firm maintains its Buy rating and $35 price target on Repros.
12:45 EDTRPRXOn The Fly: Midday Wrap
Subscribe for More Information
11:15 EDTRPRXRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
10:52 EDTRPRXOptions with increasing implied volatility
Options with increasing implied volatility: RPRX VALE NLY AGNC
07:19 EDTRPRXRepros Therapeutics sell-off overdone, says Brean Capital
Brean Capital said the selling in Repros Therapeutics is overdone after an FDA panel voted overwhelmingly in support for a more restrictive label that limits the use of TRT drugs to only patients with classic hypogonadism. The firm feels since Androxal has not been targeting age-related hypogonadism it does not deserve to be negatively impacted by yesterday's ruling. Brean Capital maintains its Buy rating on Repros Therapeutics and $41 price target on the shares.
07:00 EDTRPRXRepros Therapeutics price target lowered to $13 from $24 at Piper Jaffray
Subscribe for More Information
06:10 EDTRPRXFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use